Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients

Clinical Biochemistry

Volumn 44, Issue 13, 2011, Pages 1062-1066

  Dewit, O ^a   Moreels, T ^b   Baert, F ^c   Peeters, H ^d   Reenaers, C ^e   de Vos, M ^d   Van Hootegem, Ph ^f   Muls, V ^g   Veereman, G ^h   Mana, F ⁱ   Van Outryve, M ^b   Holvoet, J ^j   Naegels, S ^j   Piessevaux, H ^c   Horsmans, Y ^c   Gala, J L ^c  

^a UCL Saint Luc   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c HHR   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e ULG   (Belgium)

^f AZ St Lucas   (Belgium)

^g SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^h Queen Paola Children's Hospital   (Belgium)

ⁱ VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^j ZiekenhuisNetwerk Antwerpen   (Belgium)

more..

Author keywords

Azathioprine; IBD; Leucopenia; Myelosuppression; TPMT; TPMT mutations

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DISEASE COURSE; DNA METHYLATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GENE MUTATION; GENOTYPE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCYTOPENIA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THROMBOCYTOPENIA; WILD TYPE;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; DNA MUTATIONAL ANALYSIS; DRUG HYPERSENSITIVITY; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LEUKOPENIA; MALE; METHYLTRANSFERASES; MIDDLE AGED; MUTATION; PANCYTOPENIA; PURINE-PYRIMIDINE METABOLISM, INBORN ERRORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80051697170     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.06.079     Document Type: Article

References (23)

1. Bean R.H. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962, 49(2):592-593.
2. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119(4):895-902.
3. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130(3):940-987.
4. Hindorf U., Lindqvist M., Hildebrand H., Fagerberg U., Almer S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24(2):331-342.
5. Gisbert J.P., Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008, 103(7):1783-1800.
6. Gearry R.B., Barclay M.L., Burt M.J., Collett J.A., Chapman B.A. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004, 13(8):563-567.
7. Warman J.I., Korelitz B.I., Fleisher M.R., Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003, 37(3):220-225.
8. Pearson D.C., May G.R., Fick G.H., Sutherland L.R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995, 123(2):132-142.
9. Eklund B.I., Moberg M., Bergquist J., Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 2006, 70(2):747-754.
10. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 32(5):651-662.
11. Derijks L.J., Wong D.R. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des 2010, 16(2):145-154.
12. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997, 126(8):608-614.
13. Rossi A.M., Bianchi M., Guarnieri C., Barale R., Pacifici G.M. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001, 57(1):51-54.
14. Travis S.P., Stange E.F., Lemann M., Oresland T., Chowers Y., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006, 55(Suppl 1):i16-i35.
15. Colombel J.F., Ferrari N., Debuysere H., Marteau P., Gendre J.P., Bonaz B., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118(6):1025-1030.
16. Lee D., Szumlanski C., Houtman J., Honchel R., Rojas K., Overhauser J., et al. Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos 1995, 23(3):398-405.
17. Gala J.L., Heusterspreute M., Loric S., Hanon F., Tombal B., Van Cangh P., et al. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998, 44(3):472-481.
18. Evans W.E. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004, 26(2):186-191.
19. Kennedy D.T., Hayney M.S., Lake K.D. Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996, 30(9):951-954.
20. Dewit O., Vanheuverzwyn R., Desager J.P., Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment Pharmacol Ther 2002, 16(1):79-85.
21. Gilissen L.P., Bierau J., Derijks L.J., Bos L.P., Hooymans P.M., van Gennip A., et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther 2005, 22(7):605-611.
22. Lowry P.W., Franklin C.L., Weaver A.L., Szumlanski C.L., Mays D.C., Loftus E.V., et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001, 49(5):656-664.
23. Roblin X., Serre-Debeauvais F., Phelip J.M., Bessard G., Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18(9):917-925.